2012
DOI: 10.1016/j.jinorgbio.2012.06.013
|View full text |Cite
|
Sign up to set email alerts
|

What do we know about the reduction of Pt(IV) pro-drugs?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

11
325
0
3

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 324 publications
(339 citation statements)
references
References 90 publications
11
325
0
3
Order By: Relevance
“…This drug is a platinum(IV) prodrug that requires intracellular reduction to platinum(II) by glutathione and ascorbate (Wexselblatt & Gibson 2012), as well as aquation of its chloride ligands, before it can bind DNA (Fig. 2).…”
Section: La-12mentioning
confidence: 99%
“…This drug is a platinum(IV) prodrug that requires intracellular reduction to platinum(II) by glutathione and ascorbate (Wexselblatt & Gibson 2012), as well as aquation of its chloride ligands, before it can bind DNA (Fig. 2).…”
Section: La-12mentioning
confidence: 99%
“…It is a common assumption that Pt IV complexes are converted into active species by biological molecular reductants, such as glutathione or ascorbic acid, under physiological conditions 37. Nevertheless, NOX‐catalyzed activation of 1 and 2 in the presence of 2 m m NADH is rapid and suggests that flavoproteins can provide alternative and highly efficient activation pathways for metallodrugs 38…”
mentioning
confidence: 99%
“…13,14 In bifunctional Pt(IV) prodrugs a bioligand is often coordinated to a Pt(IV) centre by a carboxylate functionality. These ligands generally play a role (i) in drug targeting and delivery or (ii) possess inherent anticancer properties.…”
mentioning
confidence: 99%